P/E ratio for Sellas Life Sciences (SLS)
P/E ratio as of May 2024 (TTM): -0.8710
According to Sellas Life Sciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.870968. At the end of 2022 the company had a P/E ratio of -1.06.
P/E ratio history for Sellas Life Sciences from 2008 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.06 | -74.55% |
| 2021 | -4.16 | 52.43% |
| 2020 | -2.73 | 1269.58% |
| 2019 | -0.1992 | -34.1% |
| 2018 | -0.3022 | -52.25% |
| 2017 | -0.6329 | -21.7% |
| 2016 | -0.8083 | -77.45% |
| 2015 | -3.59 | -28.77% |
| 2014 | -5.03 | -13.74% |
| 2013 | -5.84 | 151.72% |
| 2012 | -2.32 | 55.37% |
| 2011 | -1.49 | -62.2% |
| 2010 | -3.95 | 6.39% |
| 2009 | -3.71 | -31.44% |
| 2008 | -5.41 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -4.37 | 401.39% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.